Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AAV8.hLCA5

Gene therapy (AAV vector) · Gene replacement · developed by Opus Genetics

Phase 1/2 Most advanced trial

IRD Developer

1 Registered trials

What is AAV8.hLCA5?

AAV8.hLCA5 is an adeno-associated virus serotype 8 vector carrying the human LCA5 gene, delivered to deliver a working copy of the gene into the retina. It is being studied in retinal degeneration associated with LCA5 gene mutations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Gene therapy (AAV vector)
Mechanism: Gene replacement
Therapy area: Ophthalmology
Developer: Opus Genetics, Inc (IRD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05616793	Phase 1/2	LCA5	Recruiting	IRD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

LCA5

More from Opus Genetics

Erenapurstat Phase 2 OPGx-RDH12 Phase 1/2

Sources

ClinicalTrials.gov NCT05616793

Updated Oct 11, 2026. Something wrong or missing? Report it on the IRD page.

Follow IRD, the company behind AAV8.hLCA5

See IRD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IRD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z